Both meta-analyses also evaluated the results of ICI therapy in PD-L1-positive NSCLC, but there have been no reports on the efficacy of ICIs in patients with EGFR-mutated NSCLC and high PD-L1 expression. This evidence concerns the gene EGFR and non-small cell lung carcinoma.